AF
VIGL

Amalgamated Financial’s Vigil Neuroscience VIGL Stock Holding History

Amalgamated Financial’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$17K Buy
+2,451
New +$32.3K ﹤0.01% 2790

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Amalgamated Financial's VIGL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Vigil Neuroscience (VIGL) in Q1 2022: 2,451 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #2790 among its holdings.

47 funds tracked by Wall St. Rank hold VIGL as of Q1 2022.

  • Amalgamated Financial held 2,451 shares of Vigil Neuroscience worth $17K as of Q1 2022.
  • Vigil Neuroscience was a new Amalgamated Financial position in Q1 2022.
  • Vigil Neuroscience made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2790 holding.
  • 47 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.